How did Royalty Pharma's core cash generation perform in the first quarter of 2026?

Portfolio Receipts rose 10% to $925 million, Adjusted EBITDA (non-GAAP) rose to $889 million from $738 million, and Portfolio Cash Flow (non-GAAP) reached $722 million, up from $611 million. Net cash provided by operating activities was $718 million.

What changed in the 2026 guidance?

Portfolio Receipts guidance was raised to $3,325 million to $3,450 million from $3,275 million to $3,425 million. The guidance excludes transactions announced after May 6, 2026, and implies Royalty Receipts growth of 4% to 8%. Payments for operating and professional costs remain at 5.5% to 6.5% of Portfolio Receipts, and interest paid is unchanged at $350 million to $360 million.

Which products drove growth and which declined?

Tremfya, Voranigo and Evrysdi drove the increase in Royalty Receipts. Tremfya rose to $64 million from $36 million, Voranigo to $47 million from $20 million, and Evrysdi to $80 million from $53 million. Promacta declined to $17 million from $44 million due to U.S. generic competition.

What new deals did the company make and how much capital did it deploy?

The company announced three royalty acquisitions for $1.25 billion in aggregate announced value, including the Ziihera royalty from Zymeworks for $250 million. It also agreed to R&D co-funding with Johnson & Johnson and Teva. Capital Deployment in the quarter was $528 million, mainly upfront payments for Ziihera and Avlayah and a Trelegy milestone payment.

What is the Tazverik impairment and what does it mean for the portfolio?

Following Ipsen's voluntary withdrawal of Tazverik from all Ipsen markets and Eisai's plan to discontinue sales in Japan, Royalty Pharma recorded $69 million of non-cash financial royalty asset impairment charges in the first quarter of 2026.

RPRX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 6, 2026. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported first quarter 2026 results on May 6, 2026, furnishing a press release as Exhibit 99.1 under Item 2.02.

Portfolio Receipts rose 10% to $925 million^a, driven by Royalty Receipts, which grew 13% to $887 million on strength from Tremfya, Voranigo and Evrysdi, partly offset by a decline from Promacta due to U.S. generic competition. Net cash provided by operating activities was $718 million, and Adjusted EBITDA (non-GAAP) was $889 million, up from $738 million. Portfolio Cash Flow (non-GAAP) was $722 million.

The company raised its full-year 2026 Portfolio Receipts guidance to $3,325 million to $3,450 million^b, from $3,275 million to $3,425 million previously, excluding future transactions. The guidance implies expected Royalty Receipts growth of 4% to 8%. Interest paid is projected at $350 million to $360 million for 2026, with approximately $175 million expected in the third quarter.

Deployment activity included three royalty acquisitions announced for $1.25 billion^c, including a Ziihera royalty bought from Zymeworks for $250 million, and R&D co-funding agreements with Johnson & Johnson (JNJ-4804, $500 million over two years) and Teva (TEV-'408, up to $500 million). Capital Deployment was $528 million in the quarter.

The company also recorded $69 million^d of non-cash impairment charges related to Tazverik. As of March 31, 2026, cash was $586 million and total debt principal was $9.2 billion.

02—Key points

Key Highlights

Portfolio Receipts grew 10% to $925 million; Royalty Receipts grew 13% to $887 million.
Net cash provided by operating activities was $718 million, versus $596 million a year earlier.
Full-year 2026 Portfolio Receipts guidance raised to $3,325 million to $3,450 million from $3,275 million to $3,425 million, excluding future transactions.
Three royalty acquisitions announced for $1.25 billion in aggregate announced value; Capital Deployment was $528 million in the quarter.
Two R&D co-funding agreements in immunology: Johnson & Johnson (JNJ-4804, $500 million over two years) and Teva (TEV-'408, up to $500 million).
Recorded $69 million of non-cash impairment charges related to Tazverik following its withdrawal from Ipsen markets.
Paid a quarterly dividend of $0.235 per share ($136 million in dividends and distributions) and repurchased about 1.1 million shares for $50 million; total debt principal was $9.2 billion at March 31, 2026.

03—Questions

Frequently Asked Questions

How did Royalty Pharma's core cash generation perform in the first quarter of 2026?
Portfolio Receipts rose 10% to $925 million, Adjusted EBITDA (non-GAAP) rose to $889 million from $738 million, and Portfolio Cash Flow (non-GAAP) reached $722 million, up from $611 million. Net cash provided by operating activities was $718 million.
What changed in the 2026 guidance?
Portfolio Receipts guidance was raised to $3,325 million to $3,450 million from $3,275 million to $3,425 million. The guidance excludes transactions announced after May 6, 2026, and implies Royalty Receipts growth of 4% to 8%. Payments for operating and professional costs remain at 5.5% to 6.5% of Portfolio Receipts, and interest paid is unchanged at $350 million to $360 million.
Which products drove growth and which declined?
Tremfya, Voranigo and Evrysdi drove the increase in Royalty Receipts. Tremfya rose to $64 million from $36 million, Voranigo to $47 million from $20 million, and Evrysdi to $80 million from $53 million. Promacta declined to $17 million from $44 million due to U.S. generic competition.
What new deals did the company make and how much capital did it deploy?
The company announced three royalty acquisitions for $1.25 billion in aggregate announced value, including the Ziihera royalty from Zymeworks for $250 million. It also agreed to R&D co-funding with Johnson & Johnson and Teva. Capital Deployment in the quarter was $528 million, mainly upfront payments for Ziihera and Avlayah and a Trelegy milestone payment.
What is the Tazverik impairment and what does it mean for the portfolio?
Following Ipsen's voluntary withdrawal of Tazverik from all Ipsen markets and Eisai's plan to discontinue sales in Japan, Royalty Pharma recorded $69 million of non-cash financial royalty asset impairment charges in the first quarter of 2026.

04—Continue

← View all 8-K filings